(Rac)-Hesperetin
Based on 1 Customer Validation
(Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.28%
- CAS. Nr.: 69097-99-0
- Formel: C16H14O6
- Molecular Weight:302.28
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-W011641
(±)-NaringeninAnti-inflammatory Agents -
HY-K2014
PEI Transfection Reagent -
HY-10256
Adezmapimodp38 MAPK Inhibitor -
HY-N0168AR
(Rac)-Hesperetin (Standard)Racemate of Hesperetin -
HY-10578
PD 169316p38 MAP Kinase Inhibitor -
HY-N7128
FlavanoneFlavones -
HY-10256R
Adezmapimod (Standard)p38 MAPK Inhibitor -
HY-N0674A
Dehydrocorydaline chloridep38 MAPK Activator -
HY-10578R
PD 169316 (Standard)Standard of PD 169316 -
HY-W011641R
(±)-Naringenin (Standard) -
HY-14305A
BMS-582949 hydrochloridep38α MAPK Inhibitor -
HY-N7128R
Flavanone (Standard)Flavones
Biologische Aktivität
Beschreibung
In Vitro
Hesperetin (25, 50, 100 μM; 0, 24, 48, 72 h) significantly inhibits the migratory capacity of TGF-β1-induced human triple-negative breast cancer MDA-MB-231 cells in a dose-dependent manner[1].
Hesperetin (500 μg/mL; 36 h) significantly inhibits the expression of ORF39 and ORF59 proteins of CCV, completely alleviates the cytopathic effect on CCO cells induced by CCV infection, and exerts a cytoprotective effect[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human triple-negative breast cancer MDA-MB-231 cells
-
Concentration:25, 50, 100 μM
-
Incubation Time:24, 48, 72 h
-
Result:Significantly inhibited TGF-β1-induced migration of MDA-MB-231 cells in a dose-dependent manner at 24 h, 48 h and 72 h after treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57 male mice (8 weeks old, 18-22 g) with LPS-induced acute lung injury[3]
-
Dosage:Hesperetin: 10 mg/kg, 20 mg/kg , 30 mg/kg ;
Positive control: 2 mg/kg Dexamethasone (oral gavage) -
Administration:oral gavage
-
Result:At 1 h after LPS intratracheal instillation, significantly suppressed the levels of interleukin-6 and tumor necrosis factor-α in bronchoalveolar lavage fluid, reduced the number of inflammatory cells in bronchoalveolar lavage fluid, ameliorated LPS-induced histopathologic changes of lung tissue and decreased lung inflammatory scores.
Reduced the lung wet/dry weight ratio, lowered the activities of myeloperoxidase and lactate dehydrogenase in lung tissue, enhanced superoxide dismutase activity, and downregulated the protein expression of Toll-like receptor 4 and myeloid differentiation factor 88 in lung tissue.
Suppressed the phosphorylation of nuclear factor-κB p65, IκB-α and TAK1, and inhibited the activation of nuclear factor-κB pathway in lung tissue, with the 30 mg/kg dosage showing the most significant therapeutic effect.
Chemical Information
-
CAS. Nr. 69097-99-0
-
Appearance Solid
-
Molecular Weight 302.28
-
Formel C16H14O6
-
Color White to yellow
-
SMILES
O=C1CC(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 116.67 mg/mL (385.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Lu Q, et al. Hesperetin Inhibits TGF-β1-Induced Migration and Invasion of Triple Negative Breast Cancer MDA-MB-231 Cells via Suppressing Fyn/Paxillin/RhoA Pathway. Integr Cancer Ther. 2022;21:15347354221086900. [Content Brief]
[3]. Wang N, et al. Hesperetin ameliorates lipopolysaccharide-induced acute lung injury in mice through regulating the TLR4-MyD88-NF-κB signaling pathway. Arch Pharm Res. 2019;42(12):1063-1070. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3082 mL | 16.5410 mL | 33.0819 mL | 82.7048 mL |
| 5 mM | 0.6616 mL | 3.3082 mL | 6.6164 mL | 16.5410 mL | |
| 10 mM | 0.3308 mL | 1.6541 mL | 3.3082 mL | 8.2705 mL | |
| 15 mM | 0.2205 mL | 1.1027 mL | 2.2055 mL | 5.5137 mL | |
| 20 mM | 0.1654 mL | 0.8270 mL | 1.6541 mL | 4.1352 mL | |
| 25 mM | 0.1323 mL | 0.6616 mL | 1.3233 mL | 3.3082 mL | |
| 30 mM | 0.1103 mL | 0.5514 mL | 1.1027 mL | 2.7568 mL | |
| 40 mM | 0.0827 mL | 0.4135 mL | 0.8270 mL | 2.0676 mL | |
| 50 mM | 0.0662 mL | 0.3308 mL | 0.6616 mL | 1.6541 mL | |
| 60 mM | 0.0551 mL | 0.2757 mL | 0.5514 mL | 1.3784 mL | |
| 80 mM | 0.0414 mL | 0.2068 mL | 0.4135 mL | 1.0338 mL | |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3308 mL | 0.8270 mL |
(Rac)-Hesperetin Related Classifications
HY-N0168A Related Classifications
Powered by Bioz